Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Transverse Myelitis Probably Associated With SARS-CoV-2 mRNA Vaccines: Two Case Reports.
COVID-19 vaccine
autoimmune diseases of the nervous system
demyelinating diseases
optic neuritis
transverse myelitis
Journal
The Neurohospitalist
ISSN: 1941-8744
Titre abrégé: Neurohospitalist
Pays: United States
ID NLM: 101558199
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
28
6
2022
Statut:
ppublish
Résumé
Post-vaccination CNS demyelinating syndromes have been reported with a variety of vaccines including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. We report a case of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) probably associated with the mRNA-1273 (by Moderna) SARS-CoV-2 mRNA vaccine, and a case of acute transverse myelitis (ATM) probably associated with the BNT162b2 (by Pfizer-BioNTech) SARS-CoV-2 mRNA vaccine. A 38-year-old man developed left blurry vision, lower extremity weakness/paresthesia, and bowel/bladder dysfunction three days after receiving the Moderna vaccine. He was diagnosed with left optic neuritis and longitudinally extensive transverse myelitis; he tested positive for the myelin oligodendrocyte glycoprotein antibody. A 39-year-old woman presented with progressive lower extremity weakness/numbness 7 days after receiving the Pfizer vaccine. She was diagnosed with ATM. Both patients improved with intravenous corticosteroids. The association between CNS demyelinating syndromes and vaccination has been reported for many years. We describe two cases of acute CNS demyelinating events probably associated with both mRNA variations of the SARS-CoV-2 vaccines. While the risk of CNS demyelinating events is non-negligible, the incidence is very low and the overall benefits of vaccination outweigh the marginal risk. However, providers should be aware of this potential neurological complication of the SARS-CoV-2 mRNA vaccines.
Identifiants
pubmed: 35755241
doi: 10.1177/19418744221090426
pii: 10.1177_19418744221090426
pmc: PMC9214935
doi:
Types de publication
Case Reports
Langues
eng
Pagination
536-540Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Gyang has received personal compensation for consultation with Genentech, EMD Serono, and Greenwich Biosciences, Inc.
Références
Adv Vet Med. 1999;41:733-47
pubmed: 9890057
Ann Neurol. 2021 May;89(5):856-857
pubmed: 33710649
Nat Rev Rheumatol. 2009 Nov;5(11):648-52
pubmed: 19865091
Autoimmun Rev. 2014 Mar;13(3):215-24
pubmed: 24514081
Mult Scler Relat Disord. 2021 May;50:102857
pubmed: 33647592
J Neurol. 2022 Mar;269(3):1093-1106
pubmed: 34480607
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946748
Acta Neurol Belg. 2022 Jun;122(3):793-795
pubmed: 33527327
Mult Scler Relat Disord. 2021 Oct;55:103189
pubmed: 34375861
QJM. 2021 Nov 5;114(8):591-593
pubmed: 33787891
Int J MS Care. 2020 Mar-Apr;22(2):85-90
pubmed: 32410903
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62
pubmed: 25635259
J Neuroimmunol. 2021 Sep 15;358:577606
pubmed: 34182207
Acta Neurol Belg. 2021 Aug;121(4):859-866
pubmed: 33934300
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1144-1151
pubmed: 34362855